Ground-breaking ceremony for the Rösslimatt Quarter: MSD is pleased to announce the start of construction of its new site in Lucerne
07.09.2022 17:00 Europe/Zurich
Lucerne, 7 September 2022 – MSD (Merck Sharp & Dohme) group Switzerland celebrated the groundbreaking ceremony for the new quarter on the Rösslimatt site in Lucerne today with SBB and partners. After completion, 650 employees from three of the five MSD Switzerland branches will be working there. The modern premises are designed to promote integrated, sustainable working practices and synergies.
MSD is pleased to participate in today’s kick-off for the construction of the centrally located Rösslimatt Quarter, which is being built near the railway station, next to the new location of the Lucerne University. On 15,000 m2 of rented space, MSD will in future unite three of the five locations and thus 650 workstations, with an expansion option of up to 850 workstations, at a common address. With the move to the planned completion in 2025, MSD is consciously remaining loyal to Lucerne. The city and canton have supported MSD for around 60 years with a stable and reliable environment. This is a valuable prerequisite for achieving the company’s goal of using leading-edge science to save and improve lives around the globe.
Thus, with the move, MSD is not only relying on new impulses for even more intensive cross-team collaboration, but also on the expansion of existing synergies. “At MSD, the ways of working are anchored in the corporate strategy,” explains Dr. Ans Heirman, Managing Director of MSD Switzerland, “Rösslimatt, with its modern space concept, will enable us to really live these in our everyday work life – for example, agile, hybrid, team-based working. The new headquarters for the Swiss and regional business also strengthens our image as a top employer in Lucerne and far beyond the region and is expected to attract more curious, innovative minds”, continues Heirman.
An important aspect in the decision to move into the new location is also the aspect of sustainability. MSD wants to create a safe, sustainable and healthy future for people and the community through a sense of responsibility. It is therefore significant that “Rösslimatt” is certified, among other things, as a “2000-watt site under development” and is thus committed to an enormously high sustainability standard that extends over the entire life cycle of the project from planning, through construction, to operation. For MSD, in addition to sustainable real estate management during construction, the optimization of resource use at the workplace and energy-saving and environmentally friendly mobility after occupation of the future site also play a key role. Thanks to the optimal connection to the train station and the city center, the best conditions are given here.
The Rösslimatt site is intended to function as a hub of science, research and creativity. “We are convinced that in the future there will be a variety of synergies beyond the boundaries of the company. We are delighted that MSD will be moving into the heart of the Rösslimatt quarter and thus becoming part of this innovative and vibrant area,” said Fabian Peter, Head of the Department of Construction, Environment and Economic Affairs.
About MSD Merck, Sharp & Dohme
At MSD Merck, Sharp & Dohme, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.
MSD Merck, Sharp & Dohme in Switzerland
In Switzerland, MSD Merck, Sharp & Dohme employs around 1,000 people at five sites in the cantons of Lucerne and Zurich. At our site in Zurich, in “The Circle”, we operate the newly opened global innovation and development hub. Our main therapeutic areas are oncology, infectious diseases, immunology, and diabetes. We also operate a broad portfolio of vaccines for the prevention of diseases in children, adolescents, and adults. Switzerland is part of MSD’s global clinical research program with more than 30 clinical trials annually. At our site in Schachen, we manufacture drugs for global clinical trials and operate a forensic laboratory. MSD also takes local responsibility for the community and has been involved in the “Trendtage Gesundheit Luzern” and the Alliance Health competence. In 2022, MSD received the “Top Employer Switzerland” award for the tenth time in a row.
For more information, please visit msd.ch, de.msd-animal-health.ch and follow us on Twitter, LinkedIn, Facebook and YouTube.
Media department MSD Switzerland
Jean-Blaise Defago (Policy & Communications Director)
media.switzerland@msd.com | Tel. 058 618 30 30
Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
CH-NON-01788